The American Journal of Medicine
Volume 120, Issue 2 , Pages 128-132 , February 2007

Polycystic Ovary Syndrome: Diagnosis and Treatment

  • Tracy L. Setji, MD

      Affiliations

    • Dr. Tracy Setji is supported by Duke University fellowship Grant 5T32-DK-007012.
    • Corresponding Author InformationRequests for reprints should be addressed to Tracy L. Setji, MD, Department of Medicine, Division of Endocrinology, Duke University Medical Center, Box 3611, Durham, NC 27710.
    • ,
  • Ann J. Brown, MD, MHS

      Affiliations

    • Dr. Ann Brown is supported by K23HL04390-01, National Heart Lung and Blood Institute, National Institutes of Health.

References 

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25
  2. Setji TL, Brown AJ. Polycystic ovary syndrome and type 2 diabetes. In:  Feinglos MN,  Bethel MA editor. Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management. Totowa, New Jersey: Humana Press; 2006;in press
  3. Polycystic ovary syndrome writing committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005;11:126–134
  4. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165–169
  5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  6. Lord JM, Flight IHK, Norman RJ. Insulin-sensitizing drugs (metformin, troglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;3:CD003053
  7. Azziz R, Ehrmann D, Legro RS, et al. 2001 PCOS/Troglitazone Study Group Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multi-center, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86:1626–1632

PII: S0002-9343(06)00777-7

doi: 10.1016/j.amjmed.2006.06.029

The American Journal of Medicine
Volume 120, Issue 2 , Pages 128-132 , February 2007

Article Tools